

ASX RELEASE

21 November 2025

Appendix 3Y – Change of Director’s Interest Notice

In accordance with Listing Rule 3.19A.2, please see the attached Appendix 3Y – Change of Director's Interest Notice.

END

Enquiries

Anita Chow
Chief Financial Officer, Acusensus Limited
+61 408 261 554
Email: investor-relations@acusensus.com

Simon Hinsley
Investor and Media Relations
+61 401 809 653
Email: simon@nwrcommunications.com.au

This announcement is authorised by the Company Secretary of Acusensus Limited.

About Acusensus

Acusensus is a technology company that was founded in 2018 with a mission to design and develop artificial intelligence enabled road safety solutions. Collaborating with governments and commercial stakeholders to tackle distracted driving globally is Acusensus’ first priority. Acusensus has pioneered intelligent solutions that provide anywhere, anytime digital evidence that can be used in conjunction with law enforcement to drive behavioural change and improve road safety. Acusensus technology is used to detect and provide prosecutable evidence of distracted driving (mobile phone use), seatbelt compliance, speeding, railway crossing compliance and the monitoring of vehicles of interest.

Leveraging AI and sensing expertise, Acusensus also provides technology that protects workers in live traffic environments. The Forsite by Acusensus road worker safety system integrates roadside sensors, connected wearables and real time analytics to give crews early warning of approaching vehicle risks, delivering the vital seconds needed to avoid harm while generating data that helps make worksites safer over time.

Acusensus listed on the Australian Securities Exchange in January 2023. Acusensus is headquartered in Melbourne, Australia, with offices also in Sydney, Brisbane, Perth, Auckland (New Zealand), Wellington (New Zealand), Christchurch (New Zealand), London (United Kingdom) and Las Vegas (United States).

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Acusensus Limited
ABN 17 625 231 941

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Alexander Jannink
Date of last notice	4 September 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Alexander Jannink is a director, shareholder and beneficiary of Jannink & Associates Pty Ltd ACN 622 744 870 as trustee for Jannink Family Trust
Date of change	20 November 2025
No. of securities held prior to change	<ol style="list-style-type: none">15,331,066 fully paid ordinary shares.510,660 unquoted options:<ol style="list-style-type: none">210,000 unquoted options exercisable at A\$0.552 and expire on 20 April 2027;220,500 unquoted options exercisable at A\$0.552 and expire on 30 June 2027; and80,160 unquoted options exercisable at A\$0.552 and expire on 26 September 2031.307,745 unquoted performance rights.
Class	Unquoted performance rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	225,275 unquoted performance rights
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (see "Nature of change" below)
No. of securities held after change	<ol style="list-style-type: none"> 15,331,066 fully paid ordinary shares. 510,660 unquoted options: <ol style="list-style-type: none"> 210,000 unquoted options exercisable at A\$0.552 and expire on 20 April 2027; 220,500 unquoted options exercisable at A\$0.552 and expire on 30 June 2027; and 80,160 unquoted options exercisable at A\$0.552 and expire on 26 September 2031. 533,020 unquoted performance rights.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of unquoted performance rights under, and subject to, the Acusensus Equity Incentive Plan Rules as part of the remuneration of the Managing Director for the 2026 financial year following shareholder approval at the Acusensus 2025 Annual General Meeting, held on 19 November 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.